Post-Quantum Cryptography Readiness for Pharma: Preparing for the NIST PQC Transition

The pharmaceutical industry faces a cybersecurity challenge unlike any it has confronted before: a threat that does not yet fully exist but whose eventual arrival is considered virtually certain by the cryptographic community, and whose impact will retroactively compromise data that is being encrypted and stored today. Quantum computing, once a theoretical curiosity confined to physics laboratories, is progressing toward practical capability at a pace that has moved the conversation from whether quantum computers will break current encryption to when they will break it and how organizations should prepare. For the pharmaceutical industry, this timeline problem is uniquely acute because of the extraordinary longevity of pharmaceutical data. Clinical trial data from pivotal studies must be retained for decades. Proprietary research data representing billions of dollars in R&D investment retains its competitive value for the full patent lifecycle and beyond. Manufacturing records must be maintained for the commercial life of the product. And patient health information carries privacy obligations that extend indefinitely.

The critical insight that transforms the quantum threat from a distant concern into an immediate action item is the harvest-now-decrypt-later attack scenario. Nation-state adversaries and sophisticated threat actors are intercepting and storing encrypted data today, building libraries of encrypted communications, files, and database transfers with the expectation that quantum computers will enable decryption within the coming decade. For pharmaceutical organizations, this means that data encrypted with today’s standard algorithms and intercepted during transmission is not protected for the full duration of its sensitivity. A clinical trial dataset encrypted with RSA-2048 and intercepted in 2026 could potentially be decrypted by 2035, well within the regulatory retention period for that data and within the competitive relevance window for the proprietary insights it contains.

In August 2024, NIST published its first three finalized post-quantum cryptographic standards, providing the foundational algorithms that will replace the vulnerable cryptographic schemes currently protecting digital infrastructure worldwide. For pharmaceutical organizations, this publication marks the starting point of a migration that will touch every system, interface, certificate, and protocol that uses public-key cryptography. This article provides a comprehensive framework for planning and executing the post-quantum cryptographic transition in pharmaceutical environments, addressing the unique considerations that arise from the industry’s regulatory requirements, long data retention horizons, validated system landscape, and complex partner ecosystem.

The Quantum Threat to Pharmaceutical Data

Understanding the specific nature of the quantum threat to cryptography is essential for designing a proportionate and effective response. The threat is not that quantum computers will break all encryption; it is that they will break specific categories of encryption that are fundamental to how digital systems establish trust, exchange keys, and verify identities.

Public-Key Cryptography Vulnerability

The cryptographic algorithms most vulnerable to quantum attack are public-key, or asymmetric, cryptographic schemes that rely on the mathematical difficulty of factoring large numbers or computing discrete logarithms. These algorithms, including RSA, Diffie-Hellman, and elliptic curve cryptography, form the foundation of virtually all modern digital security: they are used to establish encrypted connections through TLS, to digitally sign documents and software, to authenticate users and devices through certificate-based systems, and to exchange the symmetric encryption keys that protect data in transit and at rest. A sufficiently powerful quantum computer running Shor’s algorithm could solve the mathematical problems underlying these schemes in polynomial time, effectively rendering them useless for protection against quantum-capable adversaries.

Symmetric Cryptography Resilience

Symmetric encryption algorithms such as AES, which protect data at rest and provide the bulk encryption for data in transit after key exchange, are significantly more resilient to quantum attack. Grover’s algorithm, the primary quantum algorithm applicable to symmetric ciphers, provides only a quadratic speedup, effectively halving the security level of symmetric keys. This means that AES-256, which provides 128 bits of security against quantum attack, remains secure for the foreseeable future. However, the reduced security margin means that organizations should ensure they are using AES-256 rather than AES-128 for data with long-term sensitivity, and that key management practices maintain the integrity of symmetric keys throughout their lifecycle.

Hash Function Implications

Cryptographic hash functions such as SHA-256 and SHA-3, which are used for data integrity verification, digital signatures, and certificate generation, are also affected by quantum computing but to a lesser degree than public-key algorithms. Grover’s algorithm provides a quadratic speedup for hash collision attacks, which means that SHA-256 provides approximately 128 bits of security against quantum attack, a level generally considered sufficient for the foreseeable future. Organizations should nonetheless ensure that their hash function usage meets current standards and that any use of deprecated hash functions such as SHA-1 or MD5 is eliminated as part of the overall cryptographic modernization effort.

Harvest Now, Decrypt Later: Why Pharma Is a Prime Target

The harvest-now-decrypt-later threat model transforms the quantum computing timeline from an abstract future concern into a present-day vulnerability. The logic is straightforward: if an adversary intercepts and stores encrypted data today, and quantum computers become capable of breaking the encryption within the data’s sensitivity lifetime, then the data is effectively compromised from the moment of interception, even though the decryption capability does not yet exist. This threat model is particularly relevant for pharmaceutical organizations because of the combination of exceptionally high data value and exceptionally long data sensitivity timelines.

Target Data Categories

The World Economic Forum’s 2025 analysis identified pharmaceutical data as among the most attractive targets for harvest-now-decrypt-later attacks. Specific data categories at elevated risk include proprietary drug discovery data including target identification research, lead compound structures, formulation development data, and preclinical study results. Clinical trial data including patient-level data from pivotal studies, statistical analysis plans, and interim results that could affect stock prices or competitive strategy. Manufacturing process parameters and trade secrets that represent years of process development investment. Regulatory strategy documents including submission plans, agency correspondence, and inspection preparation materials. And intellectual property filings including draft patent applications and freedom-to-operate analyses that could provide competitors with advance intelligence about pipeline direction.

Threat Actor Landscape

The adversaries most likely to pursue harvest-now-decrypt-later strategies against pharmaceutical targets are nation-state intelligence services with the resources to intercept and store large volumes of encrypted traffic and the strategic motivation to access pharmaceutical intellectual property. The pharmaceutical industry has been explicitly identified as a high-priority intelligence target by multiple intelligence agency assessments, and the COVID-19 pandemic dramatically elevated the strategic importance of pharmaceutical capabilities in national security calculations. While the specific entities conducting harvest-now-decrypt-later operations are classified, the intelligence community’s public assessments leave little doubt that pharmaceutical data is being intercepted and stored by multiple state actors with the expectation that quantum decryption will eventually make that data accessible.

NIST Post-Quantum Cryptography Standards

NIST’s post-quantum cryptography standardization program, which began in 2016 with a call for algorithm submissions and progressed through multiple rounds of evaluation, reached a landmark milestone in August 2024 with the publication of three finalized standards. These standards provide the algorithm specifications that will serve as the foundation for the global migration away from quantum-vulnerable cryptography.

ML-KEM: Module-Lattice-Based Key Encapsulation

FIPS 203 specifies ML-KEM, formerly known as CRYSTALS-Kyber, as the primary standard for key encapsulation, the mechanism used to securely exchange symmetric encryption keys between parties. ML-KEM is based on the mathematical hardness of the module learning-with-errors problem, which is believed to be resistant to both classical and quantum attack. ML-KEM is expected to be the most widely deployed PQC algorithm because it replaces the key exchange mechanisms used in TLS, VPN, and other transport security protocols that protect virtually all network communication. ML-KEM provides three parameter sets, ML-KEM-512, ML-KEM-768, and ML-KEM-1024, offering different trade-offs between security level, key size, and computational performance. For pharmaceutical organizations, ML-KEM-768, which provides a security level roughly equivalent to AES-192, is expected to be the standard choice for most applications, with ML-KEM-1024 reserved for the highest-sensitivity data classifications.

ML-DSA: Module-Lattice-Based Digital Signature Algorithm

FIPS 204 specifies ML-DSA, formerly known as CRYSTALS-Dilithium, as the primary standard for digital signatures. Digital signatures are used to verify the authenticity and integrity of data, software, certificates, and documents, and they are fundamental to the trust infrastructure that underpins TLS certificates, code signing, electronic document signing, and the public key infrastructure that manages organizational identity. ML-DSA is based on the same module learning-with-errors problem as ML-KEM, providing mathematical consistency across the PQC standard suite. For pharmaceutical organizations, ML-DSA will eventually replace the RSA and ECDSA signatures used in TLS certificates, code signing certificates for validated software, electronic signatures on GxP documents, and digital certificates used for identity authentication.

SLH-DSA: Stateless Hash-Based Digital Signature Algorithm

FIPS 205 specifies SLH-DSA, formerly known as SPHINCS+, as an alternative digital signature standard based on hash functions rather than lattice mathematics. SLH-DSA provides a diversity backup in the PQC ecosystem: because its security relies on different mathematical foundations than ML-DSA, it would remain secure even in the unlikely event that the lattice-based problems underlying ML-KEM and ML-DSA were found to be vulnerable. SLH-DSA produces larger signatures and is slower than ML-DSA, making it less suitable for high-volume signature operations, but it provides a valuable option for applications where signature size and speed are less critical than cryptographic diversity, such as code signing and root certificate signing.

Cryptographic Inventory: Mapping Your Exposure

The first practical step in preparing for the post-quantum transition is conducting a comprehensive cryptographic inventory that identifies every use of public-key cryptography across the organization’s technology landscape. This inventory provides the foundation for risk assessment, migration prioritization, and resource planning. Without a thorough understanding of where quantum-vulnerable cryptography is deployed, organizations cannot make informed decisions about migration sequencing or resource allocation.

Inventory Scope and Methodology

The cryptographic inventory should encompass all categories of public-key cryptography usage across the enterprise, including TLS certificates protecting web applications, APIs, and internal services, VPN configurations that protect site-to-site and remote access connections, code signing certificates used to verify the authenticity and integrity of software deployments, email encryption and signing certificates, document signing capabilities including electronic signatures on GxP documents, database encryption configurations including transparent data encryption and column-level encryption, file and disk encryption implementations, certificate authorities and public key infrastructure components, key management systems and hardware security modules, and SSH keys used for system administration and secure file transfer.

For each identified use of public-key cryptography, the inventory should document the specific algorithm and key length in use, the system or service that depends on the cryptographic capability, the data classification of the information protected by the cryptography, the estimated timeline for migration based on system lifecycle and change control constraints, and any dependencies on external parties such as certificate authorities, cloud providers, or partner organizations that may affect migration timing.

Automated Discovery Tools

Given the scale of cryptographic usage in a typical pharmaceutical organization, manual inventory approaches are insufficient. Organizations should deploy automated cryptographic discovery tools that can scan network traffic to identify TLS connections and their cipher suite configurations, inventory certificates across the enterprise including those stored in certificate stores, key stores, and configuration files, analyze code repositories to identify hard-coded cryptographic configurations, and scan cloud infrastructure to identify cryptographic services and their configurations. Several commercial and open-source tools are available for cryptographic discovery, and major cloud providers offer native services for inventorying cryptographic usage within their platforms.

Data Classification for Quantum Risk

Not all data faces the same level of quantum risk, and the migration to post-quantum cryptography should be prioritized based on a data classification scheme that considers both the sensitivity of the data and the duration for which that sensitivity persists. This classification enables organizations to focus their initial migration efforts on the data that faces the greatest quantum risk while developing the capabilities and experience needed for broader migration.

Quantum Risk Classification Framework

A practical quantum risk classification framework for pharmaceutical organizations should categorize data into tiers based on the intersection of sensitivity and time horizon. The highest priority tier encompasses data with long-term sensitivity exceeding fifteen years and high confidentiality requirements, including clinical trial patient data, proprietary drug discovery intellectual property, and trade secret manufacturing processes. The second tier encompasses data with medium-term sensitivity of five to fifteen years and significant confidentiality requirements, including regulatory submission data, competitive intelligence, and partnership agreements. The third tier encompasses data with short-term sensitivity of less than five years, including routine business communications, operational data, and information that will lose its sensitivity before quantum computing achieves cryptographic relevance. Migration should begin with the first tier immediately, proceed to the second tier as organizational capability and vendor support mature, and address the third tier as part of the routine technology refresh cycle.

PQC Migration Planning and Prioritization

The migration from classical to post-quantum cryptography will be one of the largest and most pervasive technology transitions in the history of information technology, affecting every system that uses public-key cryptography and requiring coordination across organizational boundaries, supply chains, and regulatory frameworks. For pharmaceutical organizations, the migration must be executed within the constraints of GxP validation requirements, regulated change control processes, and the imperative to maintain uninterrupted operations throughout the transition.

Migration Sequencing Strategy

The migration should be sequenced to address the highest-risk data first while building organizational capability incrementally. A practical sequencing strategy begins with data-at-rest encryption for the highest-sensitivity data stores, including clinical trial databases, intellectual property repositories, and research data warehouses. This is often the most straightforward migration starting point because it can be executed through infrastructure-level changes such as re-encryption with PQC algorithms without modifying the applications that use the data. Next, data-in-transit protection for connections that carry the highest-sensitivity data should be upgraded to post-quantum TLS configurations. This requires both server-side and client-side support for PQC algorithms, which may depend on vendor readiness for some commercial applications. Following these priorities, digital signature migration for the most critical use cases, including code signing for validated software and electronic signatures on GxP documents, should be addressed. This is typically the most complex migration area because digital signatures are embedded in trust chains that span multiple organizations and systems. Finally, enterprise-wide cryptographic migration covering all remaining public-key cryptography usage should be completed, potentially extending over several years as vendor support matures and as systems reach their natural refresh points.

Crypto-Agility: Building Adaptive Cryptographic Architecture

Crypto-agility, the ability to rapidly and efficiently transition between cryptographic algorithms without requiring extensive system modification, is the most important architectural principle to embed in systems being deployed or upgraded today. The post-quantum transition is the immediate motivator for crypto-agility, but the principle has enduring value because cryptographic standards will continue to evolve as new mathematical insights, new attack techniques, and new computing capabilities emerge over time.

Architectural Principles for Crypto-Agility

Crypto-agile systems abstract cryptographic algorithms behind well-defined interfaces, allowing algorithms to be swapped without modifying application logic. Configuration-driven algorithm selection enables cryptographic changes through configuration rather than code modification, supporting the rapid response times that security vulnerabilities may require. Centralized cryptographic services reduce the number of places where algorithm changes must be made by concentrating cryptographic operations in shared services rather than embedding them in individual applications. Automated key management ensures that key generation, distribution, rotation, and retirement processes are automated and algorithm-independent, enabling seamless operation with both classical and post-quantum algorithms. And comprehensive cryptographic monitoring provides visibility into which algorithms are in use across the enterprise, enabling organizations to track migration progress and detect non-compliant configurations.

Implementation Approaches

For pharmaceutical organizations, crypto-agility can be implemented through several practical approaches. All new system deployments and major upgrades should require crypto-agility as a non-negotiable architectural requirement, with cryptographic algorithm selection externalized to configuration rather than embedded in code. Integration platforms and API gateways should be upgraded to support PQC algorithms, providing a centralized point for cryptographic migration that covers all systems that route traffic through these platforms. Certificate management platforms should be upgraded to support PQC certificate types, enabling the issuance of hybrid certificates that contain both classical and post-quantum keys during the transition period. And key management systems and hardware security modules should be upgraded or replaced with versions that support PQC algorithms, ensuring that the foundational key management infrastructure can support the migration.

Hybrid Cryptographic Approaches for Transition

The transition from classical to post-quantum cryptography will not happen instantaneously, and during the transition period, organizations will need to maintain interoperability with partners, systems, and services that have not yet migrated. Hybrid cryptographic approaches that combine classical and post-quantum algorithms provide a practical solution for this transition period, ensuring that communications are protected by post-quantum algorithms while maintaining backward compatibility with classical-only systems.

Hybrid Key Exchange

Hybrid key exchange combines a classical key exchange mechanism such as ECDH with a post-quantum key exchange mechanism such as ML-KEM, deriving the session key from both exchanges so that the communication is secure as long as at least one of the two algorithms remains unbroken. This approach provides immediate protection against harvest-now-decrypt-later attacks because even if the classical component is eventually broken by quantum computers, the post-quantum component maintains the confidentiality of the session key. Hybrid key exchange is already being deployed in major web browsers and cloud services, and it is the recommended approach for the initial transition of TLS connections to post-quantum protection.

Hybrid Digital Signatures

Hybrid digital signatures attach both a classical signature and a post-quantum signature to the signed content, enabling verification by both classical-only and post-quantum-capable verifiers. This approach is particularly important for pharmaceutical organizations during the transition period because GxP electronic signatures must be verifiable by all parties in the regulatory ecosystem, including health authorities, contract partners, and auditors who may be at different stages of their own PQC migration. Hybrid signatures ensure that signed documents remain verifiable regardless of the recipient’s PQC capability.

GxP Implications of Cryptographic Migration

Cryptographic migration in GxP environments carries regulatory implications that must be addressed through the organization’s quality management system. Changes to the cryptographic algorithms used to protect GxP data, sign GxP documents, or secure GxP system communications constitute changes to validated systems that must be managed through established change control processes.

Validation Considerations

The validation approach for PQC migration should follow risk-based principles, applying validation rigor proportionate to the GxP impact of each cryptographic change. Changes to encryption algorithms protecting GxP data at rest require verification that the re-encrypted data remains accessible, intact, and unchanged. Changes to TLS configurations for GxP system connections require verification that data exchange continues to function correctly with the new cryptographic parameters. Changes to digital signature algorithms require verification that signed documents can be created and verified using the new algorithms, and that existing signatures created with classical algorithms remain verifiable. And changes to certificate infrastructure require verification that certificate-based authentication and authorization continue to function correctly for GxP systems.

Electronic Signature Continuity

One of the most sensitive GxP implications of the PQC transition concerns the continuity and verifiability of electronic signatures. GxP regulations require that electronic signatures remain linked to their respective electronic records and that signed records cannot be repudiated. During and after the cryptographic migration, organizations must ensure that electronic signatures created with classical algorithms prior to migration remain verifiable indefinitely, that the migration process does not invalidate or alter existing electronic signatures, that new electronic signatures created with post-quantum algorithms meet all regulatory requirements for electronic signatures including unique identification of the signer and tamper evidence, and that the organization’s electronic signature policy is updated to address the use of post-quantum algorithms and the verification procedures for both classical and post-quantum signatures.

Supply Chain and Partner Ecosystem Considerations

The pharmaceutical industry’s extensive partner ecosystem creates cryptographic interdependencies that complicate the PQC migration. Encrypted communications and digitally signed documents flow between pharmaceutical companies and contract research organizations, contract development and manufacturing organizations, regulatory authorities, healthcare providers, supply chain partners, and technology service providers. The PQC migration must be coordinated across these relationships to maintain interoperability throughout the transition.

Organizations should begin engaging key partners about PQC readiness, establishing timelines for mutual migration, and implementing hybrid cryptographic approaches that maintain interoperability during the transition period when different partners may be at different stages of migration. Vendor assessments should incorporate PQC readiness as an evaluation criterion, and contracts with critical service providers should include requirements for PQC migration within defined timelines.

Regulatory Landscape and Government Mandates

Government mandates for post-quantum cryptographic migration are accelerating, and pharmaceutical organizations that operate in regulated environments should anticipate that these mandates will increasingly affect their operations.

U.S. Federal Requirements

The National Security Memorandum on Promoting United States Leadership in Quantum Computing While Mitigating Risks to Vulnerable Cryptographic Systems, issued in January 2022, established requirements for federal agencies to inventory their cryptographic systems and develop migration plans for post-quantum cryptography. CISA’s quantum readiness guidance provides a detailed framework for organizations to assess their quantum risk and plan their migration. While these federal mandates directly apply only to federal agencies and their direct contractors, they signal the direction of regulatory expectations and are likely to influence the standards and practices that pharmaceutical regulators expect from the organizations they oversee.

Anticipated Regulatory Expectations

While no pharmaceutical regulator has yet issued specific guidance on post-quantum cryptography, the trajectory of regulatory expectations is clear. Regulators who have invested significantly in data integrity enforcement will inevitably extend their attention to the cryptographic foundations that protect data integrity. Organizations that proactively address PQC readiness will be better positioned to respond when regulatory expectations crystallize, and their early investment in PQC migration will provide competitive advantage in regulatory interactions where demonstrating leadership in data protection enhances organizational credibility.

Building the Organizational Action Plan

The post-quantum cryptographic transition requires a structured organizational action plan that coordinates activities across information security, IT operations, quality assurance, and business functions. The action plan should be integrated into the organization’s broader cybersecurity strategy and should receive executive sponsorship commensurate with the scope and strategic importance of the transition.

Immediate Actions (Next 6 Months)

Organizations should begin immediately with conducting a cryptographic inventory across all systems, focusing first on GxP systems and high-sensitivity data stores. Data classification for quantum risk should be completed for the most critical data categories. An assessment of vendor readiness for PQC should begin with critical technology providers including cloud services, certificate authorities, and security platforms. Crypto-agility should be established as a mandatory requirement for all new system deployments and major upgrades. And an executive briefing should be prepared that articulates the quantum risk to pharmaceutical data and secures organizational commitment to the PQC migration program.

Near-Term Actions (6-18 Months)

Near-term activities should include deploying hybrid key exchange for the highest-priority TLS connections, particularly those that carry first-tier data. Beginning re-encryption of highest-sensitivity data at rest with PQC algorithms. Upgrading key management infrastructure to support PQC algorithms. Engaging critical partners on PQC migration coordination. And developing the validation strategy for PQC migration across GxP systems.

Medium-Term Actions (18-36 Months)

Medium-term activities should include expanding PQC deployment across all TLS connections carrying second-tier data. Migrating digital signature capabilities to PQC algorithms, beginning with internal use cases and extending to external interactions as partner readiness permits. Completing re-encryption of all first and second-tier data at rest. Updating electronic signature policies and procedures for PQC compliance. And conducting the first comprehensive assessment of migration progress and remaining exposure.

The post-quantum cryptographic transition is not a distant problem requiring future attention; it is a present challenge requiring immediate action. The data being encrypted today with quantum-vulnerable algorithms will remain sensitive long after quantum computers achieve the capability to break those algorithms. Every month of delay in beginning the transition extends the window of exposure for the pharmaceutical industry’s most valuable and most sensitive data. The NIST standards are published. The technology is maturing. The threat is real. The time to begin is now.